Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial
Carcinoma, Renal Cell
Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC. No dose-response relationship was detected as measured by PFS. These efficacy and safety results in mRCC support study in the phase III setting.